Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.53 |
| ▸ | GRM5 | P41594 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17222886 | 0.89 | NAMPT (0.52) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL2594283 | 0.87 | GRM1 (0.65) | NAMPTPDK4GRM1GRM5MAPT | |
| SCHEMBL8912847 | 0.87 | NAMPT (0.63) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL18326659 | 0.85 | NAMPT (0.49) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL904049 | 0.85 | NAMPT (0.61) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL940673 | 0.85 | NAMPT (0.56) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL17229879 | 0.84 | GRM1 (0.50) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL18619842 | 0.84 | NAMPT (0.60) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL2908091 | 0.84 | NAMPT (0.60) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL18619845 | 0.84 | NAMPT (0.60) | NAMPTPDK4GRM1GRM5HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021142420-A1 | PYRAZOLO[1,5-a]PYRIMIDIN-7(4H)-ONE INHIBITORS OF DYNEIN | KAPOOR TARUN M (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021142420-A1 | PYRAZOLO[1,5-a]PYRIMIDIN-7(4H)-ONE INHIBITORS OF DYNEIN | KAPOOR TARUN M (US) | 2021-07-15 | — | — | WO | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2015014993-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2015-02-05 | — | — | WO | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-1836168-B1 | BENZOYL-TETRAHYDROPYRIDINE AS GLYT-1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | EP | disclosed |
| US-7485637-B2 | Benzoyl-tetrahydropiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1836168-A1 | BENZOYL-TETRAHYDROPYRIDINE AS GLYT-1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072432-A1 | BENZOYL-TETRAHYDROPYRIDINE AS GLYT-1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148797-A1 | Benzoyl-tetrahydropiperidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | disclosed |
| WO-2003101381-A2 | 1,2 DIAMIDO CYCLOALKYL SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-6303593-B1 | FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-10-16 | — | — | US | disclosed |
| WO-2000051608-A1 | 3-THIENYL AND 3-FURANYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | NAMPT 692/4885PDK4 165/4885GRM1 4410/4885 |
| US-20060148797-A1 | Benzoyl-tetrahydropiperidine derivatives | GRIN2A, HTR5A, BACE1 | NAMPT 2669/4885PDK4 1085/4885GRM1 79/4885 |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | NAMPT 273/4885PDK4 2762/4885GRM1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.